12,455 results match your criteria Meningococcal Infections

Vaccination and Immunoprotection in People with HIV.

Steven C Johnson

Top Antivir Med 2020 Dec-Jan;28(3):465-468

University of Colorado, Aurora, CO, USA.

Vaccines play an important role in HIV primary care and are available for several sexually transmitted infections, including those caused by hepatitis A virus (HAV), hepatitis B virus (HBV), and human papillomavirus (HPV). HAV vaccination is increasingly important, given recent hepatitis A outbreaks and lack of immunity in many adults. A novel formulation of the hepatitis B vaccine shows promise in increasing rates of seroprotection. Read More

View Article and Full-Text PDF

Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India.

Vaccine 2021 Jun 29;39(28):3737-3744. Epub 2021 May 29.

Government Kilpauk Medical College, Chennai, Tamil Nadu, India.

Introduction: A hospital-based sentinel surveillance network for bacterial meningitis was established in India to estimate the burden of bacterial meningitis, and the proportion of major vaccine-preventable causative organisms. This report summarises the findings of the surveillance conducted between March 2012, and September 2016 in eleven hospitals.

Methods: We enrolled eligible children with bacterial meningitis in the age group of one to 59 months. Read More

View Article and Full-Text PDF

Primary meningococcal arthritis in a COVID-19 18-year-old man: a case report and review of the literature.

BMC Infect Dis 2021 May 29;21(1):499. Epub 2021 May 29.

Pneumology and Infectious Diseases department, Saint-Quentin hospital, 1 avenue Michel de l'hospital, 02100, Saint-Quentin, France.

Background: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is associated with various complications. PMA (primary meningococcal arthritis) is a rare meningococcus-associated disease causing arthritis of the knee usually, without any signs of invasive meningococcal disease. No case of PMA in a COVID-19 (coronavirus disease, 2019) patient has yet been described. Read More

View Article and Full-Text PDF

Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.

Lancet Digit Health 2021 06;3(6):e360-e370

Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Dublin, Ireland; Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.

Background: Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, which are typically transmitted via respiratory droplets, are leading causes of invasive diseases, including bacteraemic pneumonia and meningitis, and of secondary infections subsequent to post-viral respiratory disease. The aim of this study was to investigate the incidence of invasive disease due to these pathogens during the early months of the COVID-19 pandemic.

Methods: In this prospective analysis of surveillance data, laboratories in 26 countries and territories across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae, and N meningitidis from Jan 1, 2018, to May, 31, 2020, as part of the Invasive Respiratory Infection Surveillance (IRIS) Initiative. Read More

View Article and Full-Text PDF

Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?

Infect Dis Now 2021 May 12. Epub 2021 May 12.

GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Créteil, France; Service de pédiatrie, Centre Hospitalier Armand Trousseau, Paris, France.

Since the beginning of the COVID-19 pandemic, reduced incidence of many viral and bacterial infections has been reported in children: bronchiolitis, varicella, measles, pertussis, pneumococcal and meningococcal invasive diseases. The purpose of this opinion paper is to discuss various situations that could lead to larger epidemics when the non-pharmaceutical interventions (NPI) imposed by the SARS-CoV-2 epidemic will no longer be necessary. While NPIs limited the transmission of SARS-CoV-2, they also reduced the spread of other pathogens during and after lockdown periods, despite the re-opening of schools since June 2020 in France. Read More

View Article and Full-Text PDF

Etiology of acute meningitis and encephalitis from hospital-based surveillance in South Kazakhstan oblast, February 2017-January 2018.

PLoS One 2021 14;16(5):e0251494. Epub 2021 May 14.

Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.

Encephalitis and meningitis (EM) are severe infections of the central nervous system associated with high morbidity and mortality. The etiology of EM in Kazakhstan is not clearly defined, so from February 1, 2017 to January 31, 2018 we conducted hospital-based syndromic surveillance for EM at the Shymkent City Hospital, in the South Kazakhstan region. All consenting inpatients meeting a standard case definition were enrolled. Read More

View Article and Full-Text PDF

Antimeningococcal Vaccination Coverage Among Healthcare Workers in an Italian University Hospital.

Front Public Health 2021 26;9:651100. Epub 2021 Apr 26.

School of Specialization in Occupational Medicine, University of Pisa, Pisa, Italy.

Following an outbreak of meningococcal epidemic in 2015 and 2016 in Tuscany, we registered a higher demand for antimeningococcal vaccination (anti-Men ACWY) by Healthcare Workers of the University Hospital of Pisa [Azienda Ospedaliero Universitaria Pisana (AOUP)]. The purpose of this work is to analyze and discuss data on vaccination coverage resulting from this vaccination campaign. We conducted a monocentric study about anti-Men vaccination in the healthcare workers of the AOUP following the outbreak of meningococcal meningitis that occurred mainly in the population of the Tuscan provinces of Pisa, Pistoia, Prato, and Florence. Read More

View Article and Full-Text PDF

Antibiotic Resistance, Typing and Clonal Analysis of Methicillin-Resistant (MRSA) Isolates from Blood of Patients Hospitalized in the Czech Republic.

Antibiotics (Basel) 2021 Apr 6;10(4). Epub 2021 Apr 6.

Centre for Epidemiology and Microbiology, National Reference Laboratory for Antibiotics, National Institute of Public Health, 10000 Prague, Czech Republic.

is one of the major causes of bloodstream infections. The aim of our study was to characterize methicillin-resistant (MRSA) isolates from blood of patients hospitalized in the Czech Republic between 2016 and 2018. All MRSA strains were tested for antibiotic susceptibility, analyzed by typing and clustered using a Based Upon Repeat Pattern (BURP) algorithm. Read More

View Article and Full-Text PDF

Atypical presentation of serogroup W disease is associated with the introduction of the 2013 strain.

Epidemiol Infect 2021 Apr 29;149:e126. Epub 2021 Apr 29.

Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, SE 70182Örebro, Sweden.

Since 2015, the incidence of invasive meningococcal disease (IMD) caused by serogroup W (MenW) has increased in Sweden, due to the introduction of the 2013 strain belonging to clonal complex 11. The aim of this study was to describe the clinical presentation of MenW infections, in particular the 2013 strain, including genetic associations. Medical records of confirmed MenW IMD cases in Sweden during the years 1995-2019 (n = 113) were retrospectively reviewed and the clinical data analysed according to strain. Read More

View Article and Full-Text PDF

Carbohydrate based meningococcal vaccines: past and present overview.

Glycoconj J 2021 Apr 27. Epub 2021 Apr 27.

GSK, Siena, Italy.

Neisseria meningitidis is a major cause of bacterial meningitidis worldwide. Children less than five years and adolescents are particularly affected. Nearly all invasive strains are surrounded by a polysaccharide capsule, based on which, 12 N. Read More

View Article and Full-Text PDF

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.

Lancet 2021 05 23;397(10286):1725-1735. Epub 2021 Apr 23.

Public Health England Colindale, London, UK; The National Institute for Health Research Health Protection Research (NIHR) Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK. Electronic address:

Background: BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled out in the UK from December, 2020. We aimed to determine the factors associated with vaccine coverage for both vaccines and documented the vaccine effectiveness of the BNT162b2 mRNA vaccine in a cohort of health-care workers undergoing regular asymptomatic testing.

Methods: The SIREN study is a prospective cohort study among staff (aged ≥18 years) working in publicly-funded hospitals in the UK. Read More

View Article and Full-Text PDF

Mortality, neurodevelopmental impairments, and economic outcomes after invasive group B streptococcal disease in early infancy in Denmark and the Netherlands: a national matched cohort study.

Lancet Child Adolesc Health 2021 Jun 21;5(6):398-407. Epub 2021 Apr 21.

Maternal, Adolescent, Reproductive & Child Health Centre and Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. Electronic address:

Background: Group B Streptococcus (GBS) disease is a leading cause of neonatal death, but its long-term effects have not been studied after early childhood. The aim of this study was to assess long-term mortality, neurodevelopmental impairments (NDIs), and economic outcomes after infant invasive GBS (iGBS) disease up to adolescence in Denmark and the Netherlands.

Methods: For this cohort study, children with iGBS disease were identified in Denmark and the Netherlands using national medical and administrative databases and culture results that confirmed their diagnoses. Read More

View Article and Full-Text PDF

Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England.

Vaccine 2021 05 13;39(19):2719-2729. Epub 2021 Apr 13.

Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.

Introduction: Invasive meningococcal disease (IMD) caused by serogroup W meningococci belonging to the ST-11 complex (MenW:cc11) has been increasing globally since the early 2000s. Penicillin resistance among meningococci due to the production of beta-lactamase remains relatively rare. Isolates displaying resistance and reduced susceptibility to penicillin due to alterations in the penA gene (encoding Penicillin Binding Protein 2) are increasingly reported. Read More

View Article and Full-Text PDF

The first laboratory confirmed invasive meningococcal disease of serogroup C with abdominal clinical presentation in Slovakia, 2019.

Epidemiol Mikrobiol Imunol 2021 ;70(1):72-75

Acute abdominal clinical presentations as initial manifestation of meningococcal infection are uncommon and frequently provoked by hyperinvasive isolates of meningococci. 10% of patients infected by the meningococcal strain, that is on the rise in Europe, suffer from abdominal pain. We hereby report the first laboratory confirmed fatal case of an otherwise healthy adult male presented with acute abdominal pain during first 24-48 hours, masking Neisseria meningitidis (N. Read More

View Article and Full-Text PDF

Meningococcal B vaccination coverage among older adolescents in the United States.

Vaccine 2021 05 10;39(19):2660-2667. Epub 2021 Apr 10.

GSK, 5 Crescent Drive, Philadelphia, PA 19112, USA. Electronic address:

Background: Serogroup B meningococcal (MenB) vaccination recommendations for adolescents in the United States (US) include routine vaccination for all individuals at increased risk and vaccination for individuals not at increased risk aged 16-23 years (preferred age 16-18 years) based on shared clinical decision-making. The two licensed MenB vaccines require administration of ≥2 doses.

Methods: This cross-sectional study analyzed 2017-2018 National Immunization Survey-Teen (NIS-Teen) data to evaluate ≥1 dose and ≥2 dose MenB vaccination coverage among adolescents aged 17 years. Read More

View Article and Full-Text PDF

Sutimlimab in Cold Agglutinin Disease.

N Engl J Med 2021 04;384(14):1323-1334

From the Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (A.R.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy (W.B.); the Centre for Waldenström's Macroglobulinaemia and Related Conditions, University College London Hospitals National Health Service Foundation Trust, London (S.D.); the Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan (Y.M.); the Division of Hematology, MedStar Georgetown University Hospital, Washington, DC (C.M.B.); the Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France (M.M.); the Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston (D.J.K.), Bioverativ, Cambridge (J.F.), and Sanofi, Waltham (X.J., S.L., C.R., J.M.-A., W.H.) - all in Massachusetts; the Department of Clinical Pharmacology, Medical University of Vienna, Vienna (B.J.); and the Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen (T.H.A.T.), and the Department of Research and Innovation, Haugesund Hospital, Haugesund (S.B.) - both in Norway.

Background: Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.

Methods: We conducted a 26-week multicenter, open-label, single-group study to assess the efficacy and safety of intravenous sutimlimab in patients with cold agglutinin disease and a recent history of transfusion. Read More

View Article and Full-Text PDF

Recognition and Management of Acute Purpura Fulminans: A Case Report of a Complication of Neisseria meningitidis Bacteremia.

Cureus 2021 Mar 4;13(3):e13704. Epub 2021 Mar 4.

Department of Medicine, Graduate Medical Education, Methodist Dallas Medical Center, Dallas, USA.

Purpura fulminans (PF) is a rare, potentially fatal complication of disseminated intravascular coagulation that is commonly associated with severe bacterial infections such as those caused by the bacterium . With the advent of vaccination, meningococcal disease has become infrequent, with a reported incidence of 1 case per 100,000 people per year. PF is an even rarer phenomenon that is only found in approximately 10 to 20% of patients with meningococcal septicemia. Read More

View Article and Full-Text PDF

A Longitudinal Study Regarding the Health Profile of the 2017 South African Hajj Pilgrims.

Int J Environ Res Public Health 2021 03 31;18(7). Epub 2021 Mar 31.

The Global Centre for Mass Gatherings Medicine, Ministry of Health, Riyadh 12341, Saudi Arabia.

The Hajj mass gathering annually attracts over two million Muslim pilgrims worldwide to the Kingdom of Saudi Arabia (KSA). We aimed to establish demographics and health profiles for the South African pilgrims performing the 2017 Hajj. This is a longitudinal survey-based study conducted on 1138 adult South African pilgrims in two phases (during and post-Hajj). Read More

View Article and Full-Text PDF

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.

Ther Adv Neurol Disord 2021 16;14:17562864211001995. Epub 2021 Mar 16.

Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.

Background: Eculizumab, a humanized monoclonal antibody targeted to terminal complement protein C5, is approved in Japan for treatment of patients with anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIg) therapy or plasmapheresis.

Methods: This interim analysis of mandatory post-marketing surveillance in Japan assessed the safety and effectiveness of eculizumab at 26 weeks after treatment initiation in patients with AChR+ gMG.

Results: Data were available for 40 adult patients in Japan [62. Read More

View Article and Full-Text PDF

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.

MMWR Morb Mortal Wkly Rep 2021 Apr 2;70(13):495-500. Epub 2021 Apr 2.

Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. Read More

View Article and Full-Text PDF

Maternal vaccines-safety in pregnancy.

Best Pract Res Clin Obstet Gynaecol 2021 Feb 19. Epub 2021 Feb 19.

Fellowship (IVF &Reproductive Medicine) Milann Fertility Centre, Bengaluru, India.

Vaccination during pregnancy is important for active immunity of the mother against serious infectious diseases, and also for passive immunity of the neonate to infectious diseases with high morbidity and mortality. As a rule, live vaccines are contraindicated during pregnancy as they may cause fetal viremia/bacteremia. Inactivated vaccines are generally safe. Read More

View Article and Full-Text PDF
February 2021

UK guidelines and testing for invasive meningococcal disease.

Lancet Infect Dis 2021 04;21(4):455-456

Immunisation and Countermeasures Division, Public Health England, Colindale, London NW9 5EQ, UK.

View Article and Full-Text PDF

ACIP recommendations for COVID-19 vaccines-and more.

J Fam Pract 2021 03;70(2):86;89;92

University of Arizona, Phoenix, USA. Email:

Prioritized immunization is advised with the 2 COVID-19 vaccines. A third meningococcal ACWY vaccine is now the only one approved for those > 55 years. Read More

View Article and Full-Text PDF

A half-century of meningococcal vaccines.

Vaccine 2021 04 19;39(17):2475-2478. Epub 2021 Mar 19.

Baystate Health, United States; University of Massachusetts Medical School-Baystate, United States. Electronic address:

The first safe and effective vaccine for the prevention of invasive meningococcal disease was created fifty years ago. The vaccine employed a novel platform, polysaccharide capsular antigen, based on the discovery that anticapsular antibody conferred protective immunity in humans. As with most new paradigms in vaccinology, it derived from important basic research from other scientific disciplines over the preceding years. Read More

View Article and Full-Text PDF

Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.

Vaccine 2021 04 18;39(16):2201-2213. Epub 2021 Mar 18.

Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, UK.

Background: Meningococcal serogroup B (MenB) has emerged as the leading cause of invasive meningococcal disease (IMD) in several countries following the release of effective vaccines against serogroups A, C, W, and Y. In 2013, however, the first multicomponent MenB vaccine (Bexsero®) was licensed in Europe.

Aim: To review the evidence on the cost-effectiveness of vaccination against MenB. Read More

View Article and Full-Text PDF

Serogroup B invasive meningococcal disease (IMD) outbreak at a Japanese high school dormitory: An outbreak investigation report from the first IMD outbreak in decades.

Vaccine 2021 04 16;39(15):2177-2182. Epub 2021 Mar 16.

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 1628640, Japan; Department of Clinical Research, National Mie Hospital, 357 Ohsato-Kubota-cho, Tsu-shi, Mie 5140125, Japan.

Purpose: The first outbreak of invasive meningococcal disease (IMD) in decades occurred in a high school dormitory in 2011. This report aims to describe the results of the IMD outbreak investigation and to discuss current issues of IMD in Japan.

Methods: We conducted an epidemiological and microbiological investigation against the IMD outbreak of serogroup B among students and staff in a high school dormitory. Read More

View Article and Full-Text PDF

Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.

Vaccine 2021 04 11;39(14):1997-2004. Epub 2021 Mar 11.

Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group, St. George's University of London, Cranmer Terrace, London SW17 0RE, UK. Electronic address:

Background: A 15-valent pneumococcal conjugate vaccine (PCV15) aims to protect against serotype 22F and 33F in addition to the serotypes within the 13-valent PCV (PCV13) which was introduced to the UK childhood immunisation programme in April 2010. Little is known about the specific epidemiology, clinical features or outcomes of invasive pneumococcal disease (IPD) due to these two serotypes.

Methods: Public Health England (PHE) conducts enhanced IPD surveillance in England. Read More

View Article and Full-Text PDF

Case 7-2021: A 19-Year-Old Man with Shock, Multiple Organ Failure, and Rash.

N Engl J Med 2021 03;384(10):953-963

From the Departments of Medicine (P.K.B.), Pediatrics (M.J.W., M.L.-R.), and Pathology (J.A.V.), Massachusetts General Hospital, and the Departments of Medicine (P.K.B.), Pediatrics (M.J.W., M.L.-R.), and Pathology (J.A.V.), Harvard Medical School - both in Boston.

View Article and Full-Text PDF